教育经历/Education
2003.9- 2008.7:中国科学院生物物理研究所, 博士
Institute of Biophysics, Chinese Academy of Sciences. PhD
1999.9- 2003.7: 南开大学，学士
Nankai University, Bachelor’s Degree
工作经历/Professional Experience
2015.3-至今: 武汉大学生命科学学院, 教授
College of Life Sciences, Wuhan University, Professor
2008.8-2015.2：美国德克萨斯大学西南医学中心分子遗传学系&霍华德休斯医学院, 博士后
Department of Molecular Genetics, UTsouthwestern Medical Center, Howard Hughes Medical Institute,
Postdoctoral
研究概述/Research Description：
高血脂是导致心脑血管疾病、脂肪肝、胰岛素抵抗等各类代谢性疾病的重要危险因素。营养过剩及不良生活习惯是诱发高血脂的重要原因，而不同人群对这些诱因的敏感程度有很大差别，这主要是由遗传因素决定。据估算，50%以上的血脂异常可归因于遗传因素。我们实验室主要感兴趣的是揭示人群中血脂异常发生发展易感性背后的遗传与分子机制，结合生物化学、细胞生物学和实验动物模型等手段阐明其发病机制与作用原理，为代谢性疾病的诊治提供理论基础。
Dyslipidemia is a leading risk factor for cardiovascular diseases, with high prevalence both in China and worldwide. Over nutrition and a sedentary life style contribute to the dyslipidemia. However, different populations have varying susceptibility to these environmental factors, underscoring the importance of genetics. Population studies suggest that over 50% of dyslipidemia cases are caused by genetics risk factors. Our research aims to elucidate the genetic risk factors underling dyslipidemia. By employing animal models, cell biology, biochemistry, and cutting-edge technologies such as gene editing, we attempt to uncover the pathological functions of key human mutations in dyslipidemia, aiming to lay the ground for novel drug discovery.
社会兼职/Social Part-time Jobs：
Elsevier期刊杂志Metabolism Open编委
Metabolism Open, Editorial Board Member
北美华人糖尿病协会会员
Chinese American Diabetes Association (CADA), Member
中国生物物理学会代谢生物学分会理事、副秘书长
Chinese Society for Metabolic Biology, CSMB, Deputy Secretary-General
中国生物化学与分子生物学学会脂质与脂蛋白专业委员会委员
Division of Lipids and Lipoprotein, CSBMB, Member
奖励荣誉/Awards and Honors：
2019：湖北省“杰青”
2017：湖北省“百人计划”青年学者
2016：武汉大学“珞珈”特聘教授
2013: Early career investigator award of excellence in Kern Lipid Conference
2011: Early career investigator award of excellence in Kern Lipid Conference
承担课程/Teaching：
本科生：《生物化学》
Undergraduates: 《Biochemistry》
主持课题项目：
1.“GPR146调节脂质代谢的功能与机制研究”，国家自然科学基金重大研究计划重点项目，负责人；
2.“PCSK9降解低密度脂蛋白受体的分子机制研究”，国家自然科学基金面上项目，负责人；
3.“进食活化ANGPTL3的分子机制及其在血脂异常发生发展中的作用机理研究”，国家自然科学基金面上项目，负责人；
4.“内体-溶酶体互作在PCSK9降解LDLR过程中的功能与机制研究”，国家自然科学基金重大研究计划培育项目，负责人；
5.“脂代谢的稳态调控与重编程”，国家自然科学基金创新群体，骨干；
6.“膜性细胞器及蛋白质机器在脂质代谢中的功能与相互作用”，科技部重点研发计划，骨干；
7.“应激对组织器官代谢稳态和发育的调控作用与机制”，科技部重点研发计划，骨干。
代表性学术论文（#并列第一作者，*通讯作者）：
1) Liu XM#, Zhang YL#, Han BQ, Li L, Li Y, Ma YF, Kang SJ, Li Q, Kong LK, Huang K, Song BL, Liu Y, Wang Y*. Postprandial exercise regulates tissue-specific triglyceride uptake through Angiopoietin-like proteins. JCI insight, 2024 Aug 22;9(16).
2) Hu X, Chen F, Jia L, Long A, Peng Y, Li X, Huang J, Wei X, Fang X, Gao Z, Zhang M, Liu X, Chen YG, Wang Y, Zhang H, Wang Y. A gut-derived hormone regulates cholesterol metabolism. Cell. 2024 Mar 28;187(7):1685-1700.e18. doi: 10.1016/j.cell.2024.02.024. Epub 2024 Mar 18.
3) Wilkins BP, Finch AM, Wang Y, Smith NJ. Orphan GPR146: an alternative therapeutic pathway to achieve cholesterol homeostasis?. Trends Endocrinol Metab. 2022 Jul;33 (7):481-492. doi: 10.1016/j.tem.2022.04.008. Epub 2022 May 10.
4) Wang JK, Li Y, Zhao XL, Liu YB, Tan J, Xing YY, Adi D, Wang YT, Fu ZY, Ma YT, Liu SM, Liu Y, Wang Y, Shi XJ, Lu XY, Song BL, Luo J. Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis. Circulation. 2022 Mar;145 (9):675-687.
5) Han FF#, Liu X#, Chen CF#, Liu YN#, Du MK, Zhou Y, Liu Y, Song BL, He HH, Wang Y*. Hypercholesterolemia risk-associated GPR146 is an orphan G-protein coupled receptor that regulates blood cholesterol levels in humans and mice. Cell Research. 2020 Apr;30(4):363-365
6) He BS#, Kang SJ#, Chen Z, Liu X, Wang JK, Li XD, Liu XM, Zheng L, Luo MC, Wang Y*. Hypercholesterolemia risk associated Abca6 does not regulate lipoprotein metabolism in mice or hamster. BBA - Molecular and Cell Biology of Lipids. 2021 Jul 15; 159006. doi: 10.1016/j.bbalip.2021.159006
7) Wang X, Wang H, Xu B, Huang D, Nie C, Pu L, Zajac GJM, Yan H, Zhao J, Shi F, Emmer BT, Lu J, Wang R, Dong X, Dai J, Zhou W, Wang C, Gao G, Wang Y, Willer C, Lu X, Zhu Y, Chen XW. Receptor-Mediated ER Export of Lipoproteins Controls Lipid Homeostasis. Cell Metab. 2021 Feb 2;33(2):350-366
8) Li XD, Zhang YL, Zhang MZ, Wang Y*. GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice. Sci Rep. 2020 Sep 30;10 (1):16168. doi: 10.1038/s41598-020-73388-3
9) Fu T, Guan YY, Xu JJ, Wang Y*. APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo. BBA - Molecular and Cell Biology of Lipids. 2017 Sep;1862(9):883-889
10) Adi D, Lu XY, Fu ZY, Wei J, Baituola G, Meng YJ, Zhou YX, Hu A, Wang JK, Lu XF, Wang Y, Song BL, Ma YT, Luo J. IDOL G51S Variant Is Associated With High Blood Cholesterol and Increases Low-Density Lipoprotein Receptor Degradation. Arterioscler Thromb Vasc Biol. 2019 Dec;39(12):2468-247
11) Chen L*, Chen XW*, Huang X*, Song BL*, Wang Y*, Wang Y*. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci. 2019 Nov;62(11):1420-1458
12) Zhang YY, Fu ZY, Wei J, Qi W, Baituola G, Luo J, Meng YJ, Guo SY, Yin H, Jiang SY, Li YF, Miao HH, Liu Y, Wang Y, Li BL, Ma YT*, Song BL*. A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption. Science. 2018 Jun 8;360(6393):1087-1092
13) Wang Y, McNutt M, Banfi S, Levin M, Holland W, Gusarova V, Gromada J, Cohen JC*, Hobbs HH*. Hepatic ANGPTL3 Regulates Adipose Tissue Energy Homeostasis. Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11630-5.
14) Wang Y, Gusarova V, Banfi S, Gromada J, Valenzuela D, Cohen JC*, Hobbs HH*. Inactivation of ANGPTL3 Reduces Hepatic VLDL-triglyceride Secretion. J Lipid Res. 2015 Jul;56(7):1308-17.
15) Wang Y#, Quagliarini F#, Gusarova V, Gromada J, Valenzuela D, Cohen JC*, Hobbs HH*. Mice Lacking ANGPTL8 (Betatrophin) Manifest Disrupted Triglyceride Metabolism Without Impaired Glucose Homeostasis. Proc Natl Acad Sci U S A. 2013 Oct 1. 110(40):16109-14
16) Quagliarini F#, Wang Y#, Kozlitina J, Grishin N, Hyde R, Boerwinkle E, Cohen JC*, Hobbs HH* . Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012 Nov 27. 109(48):19751-6
17) Wang Y, Huang Y, Hobbs HH, Cohen JC*. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res. 2012 Sep;53(9):1932-43.
18) Chen Y#, Wang Y#, Zhang J#, Deng Y, Jiang L, Song E, Wu XS, Hammer JA, Xu T*, Lippincott-Schwartz J*. Rab10 and myosin-Va mediate insulin-stimulated GLUT4 storage vesicle translocation in adipocytes. J Cell Biol. 2012 Aug 20;198(4):545-60
19) Bai L#, Wang Y#, Fan J#, Chen Y, Ji W, Qu A, Xu P, James DE* & Xu T* Dissecting multiple steps of GLUT4 trafficking and identifying the sites of insulin action. Cell Metab. 2007 Jan;5(1):47-57
代表性成果一：通过人类遗传学筛选与功能机制研究，发现首个调节血液胆固醇水平的GPCR孤儿受体GPR146，为新型降血脂药物研发提供重要靶点（Cell Research, 2020）。
基因组7p22区域非编码区SNP rs1997243通过增加GPR146表达导致高胆固醇血症
代表性成果二：通发现运动重塑机体脂质代谢稳态的新通路与新机制（JCI insight, 2024）。
运动一方面通过抑制肝脏ANGPTL8-ANGPTL3增加心脏、肌肉等能量消耗器官对甘油三酯的吸收利用，另一方面通过增加脂肪组织ANGPTL4的表达抑制脂肪组织对甘油三酯的吸收储存，从而实现组织特异性甘油三酯吸收调控。
实验室成员
合影
招生招聘
本实验室每年拟接收1名本科生，2名硕士生和2名博士生，并长期招聘博士后与副研究员，欢迎对脂质代谢感兴趣的有志青年加入。博士后、副研究员可随时联系。报考研究生的同学请在报名前将你的简历和科研兴趣/目标发送到 wang.y(at)whu.edu.cn
